Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin
切除修复交叉互补组 1 (ERCC1) 诱导动力学和多态性是接受奥沙利铂治疗的结肠直肠癌患者预后较差的标志
期刊:Oncotarget
影响因子:
doi:10.18632/oncotarget.27140
Devika Rao, Atrayee Basu Mallick, Titto Augustine, Cecilia Daroqui, Jeeshan Jiffry, Amartej Merla, Imran Chaudhary, Raviraja Seetharam, Arjun Sood, Srikanth Gajavelli, Santiago Aparo, Lakshmi Rajdev, Andreas Kaubisch, Jennifer Chuy, Abdissa Negassa, John M Mariadason, Radhashree Maitra, Sanjay Goel
